Study on the Effectiveness and Safety of Pirtobrutinib for Patients with Relapsed or Hard-to-Treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Inclusion Criteria

• Have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• Have received previous treatment for CLL/SLL.
• Have had 1 to 3 prior treatments for CLL/SLL.
• Have been treated with a covalent BTK inhibitor.
• Need treatment according to specific medical guidelines.
• Be able to swallow pills.
• Have a performance status score of 0 to 2, indicating full activity or some restriction in strenuous activities.

Exclusion Criteria

• Have been treated with a BTK degrader and a noncovalent BTK inhibitor before.
• Have experienced severe bleeding (Grade 3 or higher) due to a BTK inhibitor.
• Have known or suspected transformation to a more aggressive form of lymphoma (Richter's transformation).
• Have known or suspected involvement of the central nervous system by CLL/SLL.
• Have had another type of cancer within the last 3 years, except for certain cases like nonmelanoma skin cancer, cervical carcinoma in situ, localized prostate cancer under active surveillance, or localized breast cancer with no active disease for more than 3 years.